Hemogenyx shares: where next?
HEMO’s investment case is much strengthened since January, though the immediate cash issues remain a concern. my thoughts below. Hemogenyx. It’s been a while since I covered this oncology portfolio stock — last running through the investment case in late January 2023. I’d encourage would-be investors who are new to the company to briefly scan […]
Oxford Biodynamics shares: another oncology biotech for the portfolio
Oxford Biodynamics shares have shot up, and deservedly so. However, there will likely be a pullback for a better entry point. Oxford Biodynamics (LON: OBD) shares were changing hands for as much as 278p five years ago and had collapsed to circa 10.5p towards the end of September 2023. The share has now shot up […]
Cizzle shares: breaking down interim results
Cizzle shares now look decent value for long-term investors — a strong component for the biotech portfolio. Read the condensed update below. With a slew of AIM companies reporting results — I thought it would be a good idea to take a brief look at Cizzle for the first time since late February. Alongside Avacta […]
Investing Strategy: The Avacta Edit
Key things you need to know about investing in small cap oncology research stocks — including the best biotech on the AIM market. As a freelance financial analyst, I spend most of my time evaluating EIS-qualifying companies for high net worth investors, alongside coverage of market titans for blue chip clients. Much of this material […]
How to invest in junior biotech shares: 4 best platforms in 2023
As with every article featured here, none of this is investing or financial advice. We encourage you to conduct your own research. Here at Investing Strategy, we like to cover high-risk, high-reward shares in select sectors which provide the best opportunities in relatively short time frames. One of these sectors is biotechs (or life sciences) […]
Abingdon Health shares: another biotech stock to watch
ABDX is shortly launching a world-first saliva pregnancy test. It could become the global standard. Abingdon Health (LON: ABDX) shares have shot up by over 100% year-to-date as investors in the FTSE AIM biotech are finally starting to see some light at the end of the tunnel. The company put to bed a hotly contested […]
Cizzle shares: another biotech stock to consider for 2023
Cizzle is advancing operations in both the US and China. This recent share price surge may continue into March. Cizzle Biotechnology (LON: CIZ) is presenting at the Biomarkers conference in Manchester this morning, marking the latest development in a line of good news over the past few months. Up 91% year-to-date to 2.96p, the biotech […]
HEMO shares: another biotech stock for the portfolio
Multiple promising treatments at the pre-clinical stage biotech stock could make it a solid speculative investment for 2023 and beyond. Hemogenyx Pharmaceuticals (LON: HEMO) is not a stock for the faint-hearted. The Main Market company’s share price spiked to 13.4p in late August 2020, and then collapsed to under 3p by mid-May 2021. It then […]